KR102508288B1 - 파킨슨병의 치료 - Google Patents

파킨슨병의 치료 Download PDF

Info

Publication number
KR102508288B1
KR102508288B1 KR1020187034626A KR20187034626A KR102508288B1 KR 102508288 B1 KR102508288 B1 KR 102508288B1 KR 1020187034626 A KR1020187034626 A KR 1020187034626A KR 20187034626 A KR20187034626 A KR 20187034626A KR 102508288 B1 KR102508288 B1 KR 102508288B1
Authority
KR
South Korea
Prior art keywords
formula
compound
alkyl
hydrogen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187034626A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015257A (ko
Inventor
니틴 크리시나지 다밀
산제이 난들랄지 만드한
만노지 아트마람지 우파드하
사미어 비시와나트 메헤트레
가자난 우타마라오 치드레와르
프라발 센구프타
트리나드하 라오 치트투리
Original Assignee
썬 파마 어드밴스트 리서치 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 썬 파마 어드밴스트 리서치 컴패니 리미티드 filed Critical 썬 파마 어드밴스트 리서치 컴패니 리미티드
Publication of KR20190015257A publication Critical patent/KR20190015257A/ko
Application granted granted Critical
Publication of KR102508288B1 publication Critical patent/KR102508288B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187034626A 2016-06-02 2017-06-02 파킨슨병의 치료 Active KR102508288B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019087 2016-06-02
IN201621019185 2016-06-02
IN201621019185 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (2)

Publication Number Publication Date
KR20190015257A KR20190015257A (ko) 2019-02-13
KR102508288B1 true KR102508288B1 (ko) 2023-03-09

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034626A Active KR102508288B1 (ko) 2016-06-02 2017-06-02 파킨슨병의 치료

Country Status (27)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CA (1) CA3024976A1 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
KR102508288B1 (ko) 2016-06-02 2023-03-09 썬 파마 어드밴스트 리서치 컴패니 리미티드 파킨슨병의 치료
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMAL STORAGE DISORDERS
KR20220024463A (ko) * 2019-06-11 2022-03-03 썬 파마 어드밴스트 리서치 컴패니 리미티드 시뉴클레인병증에 대한 치료
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
AU2021317186A1 (en) 2020-07-31 2023-03-16 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease
US20250275953A1 (en) 2022-05-02 2025-09-04 Sun Pharma Advanced Research Company Ltd. Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012208388C1 (en) * 2011-01-21 2017-04-27 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
MX2017014752A (es) * 2015-05-18 2018-03-23 Sun Pharma Advanced Res Co Ltd Nuevos etinos de amidoheteroaril aroil hidrazida.
KR102508288B1 (ko) * 2016-06-02 2023-03-09 썬 파마 어드밴스트 리서치 컴패니 리미티드 파킨슨병의 치료

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Also Published As

Publication number Publication date
DK3463351T3 (da) 2022-06-07
US20240066014A1 (en) 2024-02-29
MX2018014944A (es) 2019-03-07
CN109475539A (zh) 2019-03-15
PL3463351T3 (pl) 2022-06-20
WO2017208267A1 (en) 2017-12-07
US20210015805A1 (en) 2021-01-21
EP3463351B1 (en) 2022-04-27
SI3463351T1 (sl) 2022-07-29
BR112018074439A2 (pt) 2019-03-06
RS63243B1 (sr) 2022-06-30
NZ748592A (en) 2025-11-28
UA123018C2 (uk) 2021-02-03
CL2018003431A1 (es) 2019-05-10
AU2017273415A1 (en) 2018-12-06
PT3463351T (pt) 2022-06-02
US20190275017A1 (en) 2019-09-12
LT3463351T (lt) 2022-06-10
US20220273632A1 (en) 2022-09-01
HUE059387T2 (hu) 2022-11-28
ES2914782T3 (es) 2022-06-16
SMT202200228T1 (it) 2022-07-21
MX385276B (es) 2025-03-18
PH12018502457B1 (en) 2022-01-12
EP4085912A1 (en) 2022-11-09
US10849887B2 (en) 2020-12-01
PH12018502457A1 (en) 2019-10-21
IL263188B (en) 2021-08-31
EP3463351A1 (en) 2019-04-10
KR20190015257A (ko) 2019-02-13
IL263188A (en) 2018-12-31
SG11201810294QA (en) 2018-12-28
CN109475539B (zh) 2021-12-28
US11583522B2 (en) 2023-02-21
US11813252B2 (en) 2023-11-14
CA3024976A1 (en) 2017-12-07
MY193754A (en) 2022-10-27
HRP20220683T1 (hr) 2022-07-08
CY1125285T1 (el) 2025-03-28
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
JP6974357B2 (ja) 2021-12-01

Similar Documents

Publication Publication Date Title
KR102508288B1 (ko) 파킨슨병의 치료
JP6509386B2 (ja) mTOR経路関連疾患を治療するための化合物
JP6904570B2 (ja) 脳腫瘍の治療方法
CA2559221A1 (en) Methods for the treatment of synucleinopathies
PT2370070E (pt) Utilização de pimobendano para o tratamento da cardiomiopatia hipertrófica felina
CA3173616A1 (en) Use of pyridine carbonyl derivatives as inhibitors of trpc6 for treating respiratory conditions
JP2009521470A (ja) シヌクレイン障害の治療
JP2007537184A (ja) 抗血小板剤に対する耐性を治療するためのジピリダモールの使用
HK40082665A (en) Treatment for parkinson s disease
OA19279A (en) Treatment for Parkinson's disease.
EA037697B1 (ru) Лечение болезни паркинсона
IL153439A (en) Drugs containing 3-oxadiazolyl-6,1-naphthyridine-2 (1H) - lozenges for the prevention and treatment of schizophrenia
ES2263835T3 (es) Terapia combinada contra tumores que comprende derivados de distamicina acriloil sustituidos e inhibidores proteina quinasa (serina/treonina quinasa).
BR122024006410A2 (pt) Uso do composto de fórmula i para o tratamento ou prevenção da doença de parkinson
WO2020233706A1 (zh) 一种治疗躁狂型精神障碍及精神分裂症的药物
BR112018074439B1 (pt) Uso do composto de fórmula i para o tratamento ou prevenção da doença de parkinson
JP6243844B2 (ja) トロンビン受容体アンタゴニストを有効成分とする肺高血圧症の予防治療剤
WO2025002962A1 (en) Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma
KR20050031499A (ko) 뇌허혈성 질환의 예방 및 치료용 조성물
WO2006035673A1 (ja) 虚血性心臓傷害の新保護法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200527

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220905

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220905

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200527

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20221201

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220905

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200527

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230306

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230307

End annual number: 3

Start annual number: 1

PG1601 Publication of registration